Introduction
============

Hyponatremia is defined as a plasma sodium concentration of ＜135 mEq/L and is frequently observed in clinical practice. It can cause nausea, headaches, changes in mental status, seizures, and loss of consciousness. However, the progression of hyponatremia from the acute to the chronic phase is variable. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are therapeutic medications for depression and are used in elderly patients worldwide ([@B1]). However, SSRIs and SNRIs are known to cause hyponatremia as a secondary effect of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Although all antidepressants, with the exception of mianserin, are associated with a risk of hyponatremia, duloxetine is associated with a relatively low degree of risk ([@B2]).

We herein describe the case of a patient who presented with acute progressive symptoms of hyponatremia caused by SIADH following a single dose of duloxetine and who initially showed normal serum sodium levels.

Case Report
===========

A 77-year-old woman with a history of deep vein thrombosis, hypertension, hyperlipidemia, and anxiety presented with headaches and nausea. Her daily medications prior to admission included warfarin (3.5 mg), rosuvastatin (2.5 mg), telmisartan (40 mg), famotidine (20 mg), benidipine (4 mg), and zolpidem (5 mg). This medication was not changed. In addition, she was prescribed ethyl loflazepate by her psychiatrist. She had not consumed alcohol for the past 10 years. The day before her presentation, her psychiatrist prescribed her duloxetine and discontinued ethyl loflazepate to prevent worsening anxiety. She took a single oral dose of duloxetine in the morning, after which she developed a headache and nausea. She subsequently visited her physician's hospital. At the time her systolic blood pressure was 170 mmHg, and the findings of a laboratory examination were mostly normal, including a serum sodium level of 135 mEq/L. She treated with an orally administered calcium blocker, and her systolic blood pressure and headache improved. On the night of the second day, headache and nausea developed again. She experienced confusion and called emergency services on the morning of the third day.

She was brought to our hospital and was examined at the neurology department. On examination, her blood pressure was 128/86 mmHg, her heart rate was 86 beats per minute and regular, her temperature was 36.2°C, and oxygen saturation was 100% on room air. She did not exhibit increased perspiration, unstable circulation, or muscle rigidity. She appeared euvolemic with good skin turgor and had no signs of dehydration or circulatory overload. She experienced confusion (Glasgow Coma Scale: E3V5M4). She was able to move her extremities but was unable to perform complex movements, such as sitting up.

On admission, a laboratory analysis revealed the following findings: serum sodium, 119 mEq/L; urine sodium, 187 mEq/L; serum osmotic pressure, 260 mOsm/kg; urine osmotic pressure, 529 mOsm/kg; blood urea nitrogen, 7.3 mg/dL; creatinine, 0.37 mg/dL; creatinine kinase, 1,987 IU/L; creatinine kinase-MB, 33 U/L; free triiodothyronine, 2.21 pg/mL; and free thyroxine, 1.380 ng/dL ([Table](#t001){ref-type="table"}). Lumbar puncture was not performed because she was taking warfarin and her condition improved the day after admission. Her electrocardiogram was normal and did not show any ST-T wave change. Magnetic resonance imaging revealed a hyperintense signal in the posterior part of pituitary gland on T1-weighted imaging and a hypointense signal on T2-weighted imaging ([Fig. 1](#g001){ref-type="fig"}); these findings proved that her pituitary gland was normal. Later, we found that her antidiuretic hormone (ADH) level was 1.9 pg/mL and her early morning free cortisol level was 27.8 μg/dL.

###### 

Results of Laboratory Examinations on Admission.

  -------------- -- ------------------ -- ----------- ---------
  Hematology                                          
                    WBC                   11,300      /μL
                    RBC                   439×10^4^   /μL
                    Hb                    13.3        g/dL
                    Ht                    38.5        \%
                    Plt                   7.8×10^4^   /μL
  Biochemistry                                        
                    TP                    7.1         g/dL
                    Alb                   4.2         g/dL
                    T-bil                 1.13        mg/dL
                    AST                   59          U/L
                    ALT                   26          U/L
                    LDH                   341         U/L
                    ALP                   145         U/L
                    GGT                   15          U/L
                    BUN                   7.3         mg/dL
                    Cre                   0.37        mg/dL
                    Na                    119         mEq/L
                    K                     3.6         mEq/L
                    Cl                    87          mEq/L
                    FPG                   126         mg/dL
                    CK                    1,987       U/L
                    CK-MB                 33          U/L
                    Serum osmolality      260         mOsm/kg
  Serology                                            
                    CRP                   0.02        mg/dL
  Coagulation                                         
                    PT%                   22.5        \%
                    PT-INR                2.55        
                    APTT                  38.1        s
  Endocrine                                           
                    TSH                   0.53        μIU/L
                    FT3                   2.21        pg/mL
                    FT4                   1.380       ng/dL
                    Cortisol              27.8        μg/dL
                    ADH                   1.9         pg/mL
  Urine                                               
                    Na                    187         mEq/L
                    K                     38.5        mEq/L
                    Urine osmolality      529         mOsm/kg
  -------------- -- ------------------ -- ----------- ---------

ADH: antidiuretic hormone, ALP: alkaline phosphatase, ALT: alanine aminotransferase, APTT: activated partial thromboplastin time, AST: aspartate aminotransferase, Alb: albumin, BUN: blood urea nitrogen, CK: creatine kinase, CK-MB: creatine kinase-MB, CRP: C-reactive protein, Cl : cloride, FPG: fasting plasma glucose, FT3: free triiodothyronine, FT4: free thyroxine, GGT: gamma glutamyltranspeptidase, Ht: hematocrit, K: potassium, LDH: lactate dehydroqenase, Na: sodium, PT: prothrombin time, PT-INR: prothrombin time international ratio, Plt: platelet, RBC: red blood cell, T-bil: total bilirubin, TP: total protein, TSH: thyroid stimulating hormone

![A) T1-weighted magnetic resonance imaging shows a hyperintense signal in the posterior pituitary gland. B) T2-weighted MRI shows a hypointense/isointense signal in the posterior pituitary gland.](1349-7235-58-1939-g001){#g001}

She was administered a drip infusion of normal saline due to high levels of creatinine kinase. She was treated with sodium at 469 mEq on the first day, 265 mEq on the second day, and 135 mEq on the third day. Her serum sodium levels improved the following day ([Fig. 2](#g002){ref-type="fig"}), along with her level of consciousness. Subsequently, we diagnosed her with acute symptomatic hyponatremia caused by SIADH as a result of treatment with duloxetine, based on the criteria of the Japanese Ministry of Labor, Health and Welfare. After 1 month, she showed complete improvement and her serum sodium level was 140 mEq/L.

![The time course of the serum sodium concentration and the daily sodium dose (A) (B) within 4 days after admission.](1349-7235-58-1939-g002){#g002}

The elevated creatinine kinase level was attributed to rhabdomyolysis caused by lying on the floor. However, this could not be verified because she lived alone and nobody observed her.

Discussion
==========

The symptoms of hyponatremia are non-specific and range widely, including nausea, vomiting, headache, confusion, coma, seizure, encephalopathy, and central herniation. The neurologic symptoms reflect the development of cerebral edema within a rigid skull. The initial response to acute hyponatremia is an increase in the brain interstitial pressure, which leads to shunting of extracellular fluid and solutes from the interstitial space into the cerebrospinal fluid, then into the systemic circulation. This is accompanied by efflux of the major intracellular ions, such as sodium, potassium, and chloride, from neurons ([@B3]).

Hyponatremia is divided into acute and chronic phases, based on the differences in symptoms and treatments. Acute hyponatremia resulting in cerebral edema causes acute encephalopathy because the regulatory mechanisms that maintain the cerebral volume fail due to a rapid decrease in tonicity; thus, acute symptomatic hyponatremia represents a medical emergency. Patients with euvolemic hyponatremia due to SIADH, hypothyroidism, or secondary adrenal failure will respond to treatment of the underlying condition. Thus, it is important to identify the cause of hyponatremia and to treat it immediately ([@B4]).

Duloxetine binds to plasma proteins in human blood; Bymaster et al. reported that more than 95% of duloxetine binds to plasma proteins ([@B5]). In the presence of other drugs that bind to the plasma proteins with high affinity, the level of free duloxetine in blood increases. Moreover, the simultaneous use of duloxetine and other drugs with high binding ratios will increase the levels of both medications, thereby increasing the risk of experiencing adverse effects.

Duloxetine is primarily metabolized by CYP1A2 and partially metabolized by CYP2D6 ([@B6]). Warfarin and zolpidem compete with duloxetine because these medicines are metabolized by CYP1A2 ([@B7],[@B8]). In addition, warfarin competes by binding to plasma proteins. The other medicines that this patient was taking were not associated with CYP1A2 or CYP2D6 metabolism and do not bind to plasma proteins. Thus, warfarin and zolpidem were the medications that likely enhanced the effect of duloxetine.

In the present case, acute symptomatic hyponatremia was considered to have been caused by SIADH due to duloxetine treatment. In elderly people, the renal function can be impaired ([@B9]) and ADH secretion may increase slightly ([@B10]), because the ADH secretory response to osmotic stimuli in the elderly is greater than that in younger people. Moreover, the risk of developing SIADH is high in women and individuals with a history of hyponatremia, medical comorbidities, or the intake of concomitant drugs that are known to cause hyponatremia or alter the secretion of ADH ([@B11]). In this case, the risk factors were female sex and the intake of other drugs; however, she had no history of hyponatremia.

SSRIs and SNRIs can induce secondary SIADH, probably through their effects on the serotonergic pathways. The chronic administration of sertraline, an SSRI, increases the levels of vasopressin and oxytocin in rats, suggesting that hyponatremia is a central phenomenon ([@B12]). In contrast, the vasopressin levels remained unchanged in a rat model of fluoxetine-induced hyponatremia ([@B13]). Drug interactions between SSRIs or SNRIs and other medications can also cause hyponatremia. SSRIs inhibit a number of cytochrome P450 isozymes, which leads to elevated serum concentrations of other medications, such as diuretics, which affect sodium homeostasis.

The risk of SIADH is relativity high within 2 weeks of starting SNRI treatment. Duloxetine has a lower risk of hyponatremia than other SSRIs or SNRIs ([@B2]). However, Siegel et al. reported a case of hyponatremic encephalopathy 4 days after starting duloxetine ([@B14]). Similarly, Amoako et al. reported a case of mild SIADH, in which the only symptom was nausea, 2 days after starting duloxetine ([@B15]). In this case, the single dose of duloxetine possibly induced SIADH because drug interactions between duloxetine and other drugs, particularly warfarin and zolpidem, enhanced the side effects of duloxetine. This implied that even a single dose of duloxetine can cause SIADH, depending on the drugs that are administered concomitantly.

To the best of our knowledge, this was the first report of hyponatremia caused by a single dose of duloxetine in a patient whose serum sodium levels were initially normal. The patient presented with headache and nausea approximately 12 hours after starting duloxetine; however, a laboratory examination showed a normal serum sodium level of 135 mEq/L. In this case, the patient's condition improved with a normal saline infusion 24 hours after admission and 60 hours after taking duloxetine. Since the half-life of duloxetine is 16 hours, the patient was observed in hospital for 1-2 days. This case suggests that SIADH must be considered, even if the serum sodium level is normal, particularly in symptomatic patients in whom SNRI treatment has been initiated. Headache, nausea, and high systolic blood pressure can indicate early brain edema secondary to hyponatremia, even if the serum sodium level is normal.

Conclusion
----------

When a patient presents with headache, nausea, and high systolic blood pressure after taking even a single dose of duloxetine, clinicians must consider a diagnosis of secondary SIADH, even if the serum sodium level is within the normal limits.
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